Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management.

Burson JR, Leung JG

The mental health clinician3 Feb 2026Cited by 2 (Europe PMC)

PMID41646202 (opens in a new tab)PMCIDPMC12872343 (opens in a new tab)DOI10.9740/mhc.2026.02.034 (opens in a new tab)PepBankPUB-41646202
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 23-year-old man taking lithium, lithium toxicity developed shortly after a switch from semaglutide to tirzepatide.

    In plain wordsIn one young man taking lithium, signs of lithium toxicity appeared soon after he switched from semaglutide to tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseLithium toxicity after switch from semaglutide to tirzepatide
    Study

    n = 1

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A 23-year-old male with schizoaffective disorder, bipolar type, developed lithium toxicity shortly after switching from semaglutide to tirzepatide.
    1 context sentence
    Summary · context
    Four days after his first dose of tirzepatide, he reported early symptoms of potential lithium toxicity, which progressed significantly after the second dose.
  2. 02HumanCase report or seriesSafety outcome

    In a patient on stable lithium, the 15-hour post-dose lithium level was 1.7 mEq/L after tirzepatide, with no change in renal function, hydration or other medicines.

    In plain wordsIn one patient, the lithium level rose to 1.7 mEq/L after tirzepatide, with no change in kidney function, hydration or other medicines.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSerum lithium level after tirzepatide
    Study

    n = 1

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Lithium level
    1.7 mEq/L
    15 hours post-dose, after tirzepatide

    Source sentences

    Summary
    Symptoms corresponded to a 15-hour post-dose level of 1.7 mEq/L, despite no changes in renal function, hydration status, or other concurrent medications.
    1 context sentence
    Summary · context
    A 23-year-old male with schizoaffective disorder, bipolar type, developed lithium toxicity shortly after switching from semaglutide to tirzepatide.
  3. 03HumanCase report or seriesSafety outcome

    In this patient, the Drug Interaction Probability Scale rated a probable interaction between tirzepatide and lithium.

    In plain wordsIn this one patient, a scoring scale rated an interaction between tirzepatide and lithium as probable.

    Peptide
    Tirzepatide
    Outcome
    Not applicableDrug interaction probability, tirzepatide and lithium
    Study

    n = 1

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Application of the Drug Interaction Probability Scale suggests a probable interaction between tirzepatide and lithium.
    1 context sentence
    Summary · context
    A 23-year-old male with schizoaffective disorder, bipolar type, developed lithium toxicity shortly after switching from semaglutide to tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.